Harmony Biosciences Up 4% On Securing FDA Orphan Drug Designation For Pitolisant
Shares of Harmony Biosciences Holdings, Inc. (HRMY) are up 4% on Thursday after the company's Pitolisant Tablets was granted FDA Orphan Drug designation for the treatment of idiopathic hypersomnia (IH), a rare and chronic neurological disease that is characterized by excessive daytime sleepiness.
Kumar Budur Harmony Biosciences Holdings Inc Harmony Biosciences Holdings Pitolisant Tablets Chief Medical Officer Orphan Drug Designation
Source: rttnews.com